| Chang ST |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=1.295 ------>paper_class3=2 ------>paper_class2=1 ------>vol=48 ------>confirm_bywho=jschu ------>insert_bywho=sschuang ------>Jurnal_Rank=75.0 ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=121 ------>medlineContent= ------>unit=E0102 ------>insert_date=20070421 ------>iam=3 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Leuk Lymphoma ------>paper_name=CD52 expression in non-mycotic T- and NK/T-cell lymphomas. ------>confirm_date=20070505 ------>tch_id=094004 ------>pmid=17325855 ------>page1=117 ------>fullAbstract=CD52 antigen (Campath-1) is expressed in high density by lymphocytes and monocytes. Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL). This study retrospectively investigated 97 TCL cases by immunohistochemistry using paraffin sections to elucidate the CD52 expression rates in various TCL sub-types. Fourteen cases of angioimmunoblastic T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this lymphoma sub-type. In the remaining 83 tumors, CD52 was expressed in 29 (35%) tumors including 8/17 (47%) NK/T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%) anaplastic large cell lymphomas. There was no statistical significance in CD52 expression in terms of patient age, gender, nodal vs extra-nodal presentation or tumor sub-types. The authors recommend performing CD52 immunostaining for future clinical trials of alemtuzumab on TCL patients and to correlate the staining results with treatment outcome. ------>tmu_sno=None ------>sno=15133 ------>authors2=Lu CL ------>authors3=Chuang SS ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Chang ST ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=CD52 expression in non-mycotic T- and NK/T-cell lymphomas. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2007 ------>submit_flag=None ------>publish_month=1 |